Biogen (BIIB) and Eisai said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use reaffirmed its positive opinion on lecanemab for early Alzheimer's disease, allowing the European Commission to resume its review of the drug's marketing application.
The companies said the European Commission had asked the committee to reassess lecanemab's safety data and risk minimization measures after issuing its initial opinion in November. The committee determined that no changes were needed, according to the joint statement.
Eisai leads the drug's global development and regulatory process, with Biogen co-commercializing and co-promoting it, the companies said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。